Welcome to our dedicated page for Icosavax news (Ticker: ICVX), a resource for investors and traders seeking the latest updates and insights on Icosavax stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icosavax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icosavax's position in the market.
Icosavax, a biopharmaceutical company focused on developing vaccines against respiratory diseases, has successfully closed its initial public offering (IPO) of 13,953,332 shares of common stock at $15.00 per share, raising gross proceeds of approximately $209.3 million. This offering included the underwriters' full exercise of an option to purchase an additional 1,819,999 shares. Icosavax aims to leverage its innovative virus-like particle (VLP) technology in its vaccine development pipeline, targeting diseases such as RSV and SARS-CoV-2. The company's stock trades on the Nasdaq under the symbol ICVX.
Icosavax, a biopharmaceutical company specializing in vaccine development, announced the pricing of its upsized initial public offering (IPO) of 12,133,333 shares at $15.00 each, aiming to raise approximately $182 million. The shares are set to trade on Nasdaq under the ticker symbol ICVX starting July 29, 2021, with the offering expected to close on August 2, 2021. The underwriters have a 30-day option to purchase an additional 1,819,999 shares. The company focuses on developing vaccines for respiratory diseases using its innovative virus-like particle technology.